Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AdvaMed Launches Ethics Code To Meet ‘Business And Market Realities’ In India

Executive Summary

Industry group AdvaMed says its Indian code on interactions between medtech companies and health care professionals is a first for the country.

You may also be interested in...



COVID-19 Treatment Xevudy Wins UK Approval; Preclinical Data Shows Promise Against Omicron

New developments on the COVID-19 front also include the European Medicines Agency starting a rolling review of Valneva’s investigational COVID-19 vaccine, and the UK government signing contracts with Pfizer/BioNTech and Moderna to buy more doses of their vaccines.

New EU Filings

Tabelecleucel, Atara Biotherapeutics’ advanced therapy for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease, is among the latest new medicines that have been submitted for review for potential pan-EU approval.

New EU Approvals

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, including BeiGene's Brukinsa for treating Waldenström’s macroglobulinemia.

UsernamePublicRestriction

Register

MT144644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel